Health Canada Approves AstraZeneca's Breast Cancer Therapy
Health Canada has granted a Notice of Compliance (NOC) for AstraZeneca's Enhertu, a HER2-directed antibody drug conjugate (ADC) for breast cancer treatment.
The approval is based on the Phase III DESTINY-Breast06 study findings and covers adults with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer.
- Patients must have undergone at least one endocrine therapy treatment for metastatic disease.
- They must no longer be suitable for additional endocrine treatment.
No additional quotes available.
AstraZeneca's Enhertu is now approved for use in Canada.
Author's summary: AstraZeneca's Enhertu approved in Canada.
More News
- Indonesia’s precariat protests call for stability
- Why Malaysia's Gig Workers Bill entrenches workers' dependency, not protection - Aliran
- NewJeans to Appeal Label Contract Court Decision
- DWTS’ Elaine Hendrix Shares Update After Rib Injury and Hospitalization
- Fort Walton Beach lands on Expedia's top 10 destinations for 2026
- Brave New Films Presents “Gaza: Journalists Under Fire” - The New Paltz Oracle
- Billie Eilish Calls on Billionaires to Do More for People in Need